CClinicalTrials.gg
Sign In
CompletedNCT00000224Updated Jun 24, 2005

Alternate-Day Buprenorphine. Phase V - 6

A Phase 1 interventional study of Buprenorphine in Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to participants aged 30 Years to 49 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by National Institute on Drug Abuse (NIDA) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
0
Ages
30 Years to 49 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate buprenorphine blockade challenge.

02

Conditions studied

  • Opioid-Related Disorders
03

In context

Opioid-Related Disorders

1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Lead sponsor

National Institute on Drug Abuse (NIDA) is the lead sponsor of 388 studies on the registry; 19 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Please contact site for information.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Crossover assignment
Masking
Double
Enrollment
0 participants

Interventions

  • DrugBuprenorphine
06

What researchers measure

Primary outcomes

  1. Drug use

  2. Opioid withdrawal

  3. Subjective dose estimate

  4. Drug effect characteristics: ARCI

  5. Physiological changes in: pupil diameter

  6. Physiological changes in: blood pressure

  7. Physiological changes in: heart rate

  8. Physiological changes in: respiration

  9. Physiological changes in: bup plasma levels

07

Study locations

1 site
  • Treatment Research Center
    Burlington, Vermont 05401, United States
08

References and documents

Publications

  • Bickel, Amass, Badger (in preparation) A double-blind controlled trial of buprenorphine dosing every 72 hours in opioid dependenct humans. Bickel, Amass, Badger (in preparation) A double-blind controlled trial of buprenorphine dosing every 72 hours in opioid dependent humans.
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00000224
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of Vermont
First posted
Sep 21, 1999
Start date
Feb 1993
Last update
Jun 24, 2005

Study contacts

Warren Bickel, Ph.D.
principal investigator · University of Vermont
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Opioid-Related Disorders→

Other studies from this sponsor

National Institute on Drug Abuse (NIDA)

Start the discussion